Results 41 to 50 of about 221,455 (333)

Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2021
Importance The current standard induction therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis is the combination of high-dose glucocorticoids and cyclophosphamide or rituximab.
S. Furuta, D. Nakagomi, Yoshihisa Kobayashi, M. Hiraguri, T. Sugiyama, K. Amano, T. Umibe, H. Kono, K. Kurasawa, Y. Kita, R. Matsumura, Y. Kaneko, K. Ninagawa, K. Hiromura, S. Kagami, Y. Inaba, Hideki Hanaoka, K. Ikeda, H. Nakajima   +18 more
semanticscholar   +1 more source

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.

The Lancet Rheumatology, 2021
BACKGROUND Systemic sclerosis is a connective tissue disease characterised by multiorgan fibrosis with an autoimmune background and poor prognosis. Although a few drugs have shown some efficacy in treating the disease, there remains a great unmet medical
S. Ebata, A. Yoshizaki, K. Oba, K. Kashiwabara, Keiko Ueda, Y. Uemura, T. Watadani, T. Fukasawa, S. Miura, A. Yoshizaki-Ogawa, Y. Asano, N. Okiyama, M. Kodera, M. Hasegawa, S. Sato   +14 more
semanticscholar   +1 more source

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome

JCI Insight, 2022
BACKGROUND Primary Sjögren’s syndrome (pSS) is characterized by B cell hyperactivity and elevated B-lymphocyte stimulator (BLyS). Anti-BLyS treatment (e.g., belimumab) increases peripheral memory B cells; decreases naive, activated, and plasma B cell ...
X. Mariette, F. Barone, C. Baldini, H. Bootsma, K. Clark, S. de Vita, D. Gardner, R. B. Henderson, M. Herdman, K. Lerang, P. Mistry, R. Punwaney, R. Seror, J. Stone, P. V. van Daele, A. van Maurik, N. Wisniacki, D. Roth, P. Tak   +18 more
semanticscholar   +1 more source

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma

Journal of Hematology & Oncology, 2022
Inevitable relapses remain as the major therapeutic challenge in patients with mantle cell lymphoma (MCL) despite FDA approval of multiple targeted therapies and immunotherapies.
Vivian Changying Jiang, Yang Liu, Alexa Jordan, Angela Leeming, Joseph McIntosh, Shengjian Huang, Rongjia Zhang, Qingsong Cai, Zhihong Chen, Yijing Li, Yuxuan Che, Lei Nie, Ingrid Karlsson, Linda Mårtensson, Mathilda Kovacek, Ingrid Teige, Björn Frendéus, Michael Wang   +17 more
doaj   +1 more source

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.

New England Journal of Medicine, 2019
BACKGROUND B-cell anomalies play a role in the pathogenesis of membranous nephropathy. B-cell depletion with rituximab may therefore be noninferior to treatment with cyclosporine for inducing and maintaining a complete or partial remission of proteinuria
F. Fervenza, G. Appel, S. Barbour, B. Rovin, R. Lafayette, N. Aslam, J. Jefferson, P. Gipson, Dana V. Rizk, J. Sedor, J. Simon, E. McCarthy, P. Brenchley, S. Sethi, C. Avila-Casado, H. Beanlands, J. Lieske, D. Philibert, Ting-Ting Li, L. Thomas, D. Green, L. Juncos, L. Beara-Lasic, S. Blumenthal, Amy N. Sussman, S. Erickson, M. Hladunewich, P. Canetta, L. Hebert, N. Leung, J. Radhakrishnan, H. Reich, Samir V. Parikh, D. Gipson, D. Lee, B. D. da Costa, P. Jüni, D. Cattran   +37 more
semanticscholar   +1 more source

Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy

American Journal of Ophthalmology Case Reports, 2016
Purpose: To describe the effect of rituximab on full-field electroretinography (ERG) in a patient with nonparaneoplastic autoimmune retinopathy (npAIR). Observations: A 58-year-old male patient with visual complaints, positive anti-retinal antibodies and
Gunay Uludag, Sumru Onal, Serra Arf, Isil Sayman Muslubas, Fatih Selcukbiricik, Aylin Koc Akbay, Nil Molinas Mandel   +6 more
doaj   +1 more source

Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review

Frontiers in Immunology, 2022
Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease of the skin. First-line treatment of systemic corticosteroids may cause serious adverse events.
Peng Cao, Wenjing Xu, Li-Tao Zhang
semanticscholar   +1 more source

Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

Haematologica, 2013
Rituximab is an effective treatment for autoimmune cytopenias associated with chronic lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based chemotherapy regimens, the incidence of autoimmune cytopenias has remained high ...
Clifton C. Mo, Ndegwa Njuguna, Paul V. Beum, Margaret A. Lindorfer, Berengere Vire, Elinor Lee, Gerald Marti, Wyndham H Wilson, Ronald P. Taylor, Adrian Wiestner   +9 more
doaj   +1 more source

Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease

Neurology, 2022
Background and Objectives Rituximab is used widely for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG)-IgG–associated disease (MOGAD); however, data regarding the effectiveness and safety
P. Barreras, Eleni S. Vasileiou, A. Filippatou, Kathryn C. Fitzgerald, M. Levy, C. Pardo, S. Newsome, E. Mowry, P. Calabresi, E. Sotirchos   +9 more
semanticscholar   +1 more source

Rituximab in dermatology

Actas Dermo-Sifiliográficas (English Edition), 2013
Rituximab was introduced into clinical practice as a medication with considerable potential. Its use in patients with B-cell lymphoma and rheumatoid arthritis revealed numerous indications in autoimmune diseases, many of which involve the skin, thus requiring dermatologists to become familiar with both the characteristics of anti-CD20 antibodies and ...
A, España, E, Ornilla, C, Panizo
openaire   +2 more sources